Elsevier

Clinical Therapeutics

Volume 20, Issue 1, January–February 1998, Pages 169-181
Clinical Therapeutics

Pharmaceutical Economics & Health Policy
Costs and duration of care for lower extremity ulcers in patients with diabetes

https://doi.org/10.1016/S0149-2918(98)80044-1Get rights and content

Abstract

Medical and pharmaceutical insurance claims associated with lower extremity diabetic ulcers were examined retrospectively to better understand the costs and duration of treatment in clinical practice. The study population consisted of working-age individuals (18 to 64 years old) with health care benefits provided through private employer-sponsored insurance plans. Diagnostic information contained in the claims database was used to identify the severity of the ulcers, and the charges associated with treatment were based on claims data. Claims for lower extremity ulcers were found in 5.1% of individuals with diabetes. Although many lower extremity ulcers heal with standard treatment, some are more resistant to treatment and require costly ongoing medical care. Almost half of these cases were associated with deep infection, osteomyelitis, or amputation. Total payments for treatment of lower extremity ulcers in this population averaged $2687 per patient per year, or $4595 per ulcer episode, with inpatient expenditures accounting for more than 80% of these costs. Costs were significantly higher for patients with more severe ulcers or with inadequate vascular status in the affected limb. We concluded that lower extremity ulcers occur in a large number of working-age people with diabetes and contribute significantly to the morbidity associated with this disease. The high cost of treating diabetic foot ulcers suggested by this analysis argues for the development of better treatment strategies and outcomes assessments for these patients.

References (24)

  • GE Reiber et al.

    Lower extremity foot ulcers and amputation in diabetes

  • C Grunfeld

    Diabetic foot ulcers: Etiology, treatment, and prevention

    Adv Intern Med

    (1991)
  • Cited by (207)

    • Epidemiology and socioeconomic impact of diabetes and Charcot neuroarthropathy

      2022, The Essentials of Charcot Neuroarthropathy: Biomechanics, Pathophysiology, and MRI Findings
    • Neuropathy of the elderly

      2020, Revue Neurologique
      Citation Excerpt :

      Screening is desirable (annual practice of a few simple electrophysiological clinical tests, especially to detect signs of autonomic damage), as the complications of this neuropathy are responsible for 50 to 75% of non-traumatic amputations worldwide. In patients over the age of 80, the prevalence of diabetic neuropathy is affected by the mortality induced by this disease, so it is found in 25% of patients over 80 years against 46% before this age [40]. Several types of neuropathies can be observed in diabetes.

    View all citing articles on Scopus
    View full text